Correlation of interleukin-17-producing effector memory T cells and CD4+CD25+Foxp3 regulatory T cells with the phosphate levels in chronic hemodialysis patients.

BACKGROUND AND OBJECTIVES: Hyperparathyroidism and hyperphosphatemia contribute to the inflammatory effects in chronic hemodialysis (HD) patients. Interleukin-17-producing CD4+ effector memory T (Th17) cells and CD4+CD25+Foxp3 regulatory T (Treg) cells both play critical roles in immune activation and inflammation. We investigated the relationship between the Treg and Th17 cells and the phosphate level in chronic HD patients. METHODS: 105 patients aged ≥35 years on chronic HD over 3 months were enrolled. The peripheral blood mononuclear cells were collected, cultured, and stimulated by phytohemagglutinin-L, phorbol myristate acetate, and ionomycin at different time points for T cell differentiation. RESULTS: The T cell differentiation was as follows: Th17 cells (mean±standard deviation (SD): 25.61%±10.2%) and Treg cells (8.45%±4.3%). The Th17 cell differentiation was positively correlated with the phosphate and albumin levels and negatively correlated with age. The Treg cell differentiation was negatively correlated with albumin level and age. In the nondiabetes group (n=53), the Th17 cell differentiation was predominantly correlated with the phosphate and iPTH (intact parathyroid hormone) levels as well as the dialysis vintage. CONCLUSION: Higher phosphate and iPTH levels and longer dialysis duration may increase Th17 cell differentiation, especially in the nondiabetic chronic HD patients.

Reducing scar formation by regulation of IL-1 and MMP-9 expression by using sustained release of prednisolone-loaded PDLL microspheres in a murine wound model.

In this study, we provide a new pharmacological treatment, which may prevent scar formation on wound healing and/or plastic surgery wounds. We used prednisolone to reduce scar formation in wound excision. To prolong the drug effect, prednisolone of different amounts were encapsulated in biodegradable poly(D,L-lactide) (PDLL) microspheres. In the in vitro cell healing study, prednisolone was markedly effective in reducing the growth rate of fibroblast cells according to electric cell-substrate impedance sensing results. At a higher density of prednisolone, a slower growth rate was observed (ANOVA, p < 0.05). In rat models of skin wound healing studies, results show that in postsurgery days 7 and 14, all of the wound fibrosis areas administered with 0.5 and 5 mM of prednisolone-loaded PDLL microspheres (PPM) were decreased by 6-116% compared with those of the control groups (ANOVA, p < 0.05). Adding the PPM led to reduce IL-1ß but increase MMP-9 expression levels as compared with the control groups (ANOVA, p < 0.0001). These results implies that using sustained releasing prednisolone microspheres can regulate ECM generated from fibroblasts, can avoid excess proliferation and reduce the formation of scar tissue during wound regeneration by inhibiting the degree of inflammation.

New nerve regeneration strategy combining laminin-coated chitosan conduits and stem cell therapy.

Nerve regeneration remains a difficult challenge due to the lack of safe and efficient matrix support. We designed a laminin (LN)-modified chitosan multi-walled nerve conduit combined with bone marrow stem cell (BMSC) grating to bridge a 10 mm long gap in the sciatic nerve of Sprague-Dawley rats. The repair outcome was monitored during 16 weeks after surgery. Successful grafting of LN onto the chitosan film, confirmed by immunolocalization, significantly improved cell adhesion. In vivo study showed that newly formed nerve cells covered the interior of the conduit to connect the nerve gap successfully in all groups. The rats implanted with the conduit combined with BMSCs showed the best results, in terms of nerve regrowth, muscle mass of gastrocnemius, function recovery and tract tracing. Neuroanatomical horseradish peroxidase tracer analysis of motor neurons in the lumbar spinal cord indicated that the amount and signal intensity were significantly improved. Furthermore, BMSCs suppressed neuronal cell death and promoted regeneration by suppressing the inflammatory and fibrotic response induced by chitosan after long-term implantation. In summary, this study suggests that LN-modified chitosan multi-walled nerve conduit combined with BMSCs is an efficient and safe conduit matrix for nerve regeneration.

Effects of laminin-coated carbon nanotube/chitosan fibers on guided neurite growth.

This study assesses the ability and potential of carbon nanotube (CNT)/chitosan to guide axon re-growth after nerve injuries. The CNT/chitosan fibers were produced via the coagulation and hydrodynamic focusing method. Fiber width and morphology were adjusted using such parameters as syringe pumping rate and the coagulant used. The CNT/chitosan fiber diameters were 50-300 µm for syringe pumping rates of 6-48 mL/h. Polyethylene glycol/NaOH (25%, w/w) solution was a suitable coagulant for forming fibers with small diameters. Physical property tests demonstrate that the CNT/chitosan composites had superior tensile strength and electrical conductivity compared with those of chitosan alone. The MTT and LDH tests reveal that CNT/chitosan composites were not cytotoxic. To improve the neural cell affinity of CNT/chitosan fibers, laminin was incorporated onto fiber surfaces via the oxygen plasma technique; cell adhesion ratio increased significantly from 3.5% to 72.2% with this surface modification. Immunofluorescence staining and SEM imaging indicate that PC12 cells adhered successfully and grew on the laminin (LN)-coated CNT/chitosan films and fibers. Experimental results show that PC12 grown on LN-coated CNT/chitosan fibers in vitro extend longitudinally oriented neurites in a manner similar to that of native peripheral nerves. With the inherent electrical properties of CNTs, oriented CNT/chitosan fibers have a potential for use as nerve conduits in nerve tissue engineering.

Gait analysis of spinal cord injured rats after delivery of chondroitinase ABC and adult olfactory mucosa progenitor cell transplantation.

Chondroitin sulfate proteoglycan (CSPG) is a major component of glial scar to restrict axonal regeneration in the lesion site after spinal cord injury (SCI). Chondroitinase ABC (ChABC), a bacteria enzyme, which has been demonstrated to digest the glycosaminoglycan (GAG) side chain of CSPG to promote axonal re-growth across the injured site. Our previous study suggested that long-term delivery of ChABC (1U/ml, injection volume 0.6 microl for one animal) via intrathecal catheter could decrease the inhibitory effect of limiting axonal re-growth after SCI. The functional behavior has been shown to improve following ChABC treatment. Little axons re-grow across the lesion site of the spinal cord but not enough to support axon innervations to targets. In this article, we show that ChABC administration combining olfactory mucosa progenitor cell (OMPC) transplantation can promote axonal re-growth across the lesion site and enhance the consistency of stepping in spinally transected rats. These OMPCs generated NG2(+) cell lineages after transplanting into the spinal cord parenchyma, and OMPCs were found to spread and migrate toward the lesion region of spinal cord. Moreover, the spatial and temporal characteristics of the step cycle in rats that receive a complete spinal cord transaction following continuous ChABC supply and OMPC transplantation. The gait characteristics of treated rats on a treadmill were consistent and approached that of intact rats. In future, the mechanism of restoring the injured spinal cord will be further investigated.

Chondroitinase ABC promotes axonal re-growth and behavior recovery in spinal cord injury.

In spinal cord injury, the injury could trigger some inhibitory signal cascades to promote chondroitin sulfate proteoglycans (CSPGs), the structures of scar tissues, formation. CSPGs could limit axonal regeneration mainly through the glycosaminoglycan (GAG) chain in the lesion site were suggested. We hypothesized that the digestion of CSPGs by chondroitinase ABC (ChABC) might decrease the inhibitory effects of limiting axonal re-growth after spinal cord injury. We compared the digesting products of CSPGs such as 2B6 by ChABC with the untreated control group and found no immunostaining of 2B6 in control group. The smaller size scars of ChABC-treatment were observed via CS-56, a type of CSPGs, 8 weeks after transection by immunohistochemistry. The inhibitory effects of CSPGs withdraw GAGs following ChABC-treatment would reduce, and immunopositive GAP-43 newly outgrown fibers were identified. In the animal trials, ChABC-treatment could improve motor function through BBB locomotor's test and reduce limiting ability of scar tissues to promote axonal regeneration via changing the structure of CSPGs by immunohistochemistry with GAP-43.